# Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

> **NCT03983928** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** TQB2450
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT03983928
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-03
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983928, "Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03983928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*